HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Proposes Public-Private Partnership For CIR

This article was originally published in The Rose Sheet

Executive Summary

In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.


Related Content

FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request
CIR Model For Ingredient Assessment Piques China's Interest
ICCR Adds Cosmetic Product Preservation To Agenda For Ninth Meeting
In Brief: FDA, EPA Sharing Data; Industry Lead-In-Cosmetics Petition Goes Unanswered; More
FDA Will Respond To Lipstick Lead-Limit Petition In March
Fourth Time’s A Charm? President’s FY 2016 Budget Includes Cosmetic Fees
Congressional Appropriators Urge FDA Action On Cosmetic Lead Limits
FDA Releases New Lipstick Lead Data, Putting Names To Numbers



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts